Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

"The rapid pace of enrollment underscores the interest in developing new treatment options for obesity and the potential advantages combination therapies may offer," said Jinzi J. Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "We remain on track to provide topline data from the trial in the fourth quarter of 2025." HONG KONG, July 14, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo ...